ECM27 Antibody

What is CD27 and why are CD27 antibodies important in immunotherapy research?

CD27 is a 45-50 kDa transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed on T cells, B cells, and natural killer (NK) cells, playing a critical role in lymphocyte activation, survival, and memory formation. CD27 antibodies have gained significant research interest because they function as agonists that can enhance anti-tumor immunity through multiple mechanisms:

• They provide co-stimulatory signals that promote T cell activation when combined with TCR stimulation

• They activate downstream NF-κB signaling pathways

• They can induce proliferation and cytokine production from T cells

• They may have direct cytotoxic effects against CD27-expressing tumor cells

Importantly, CD27 antibodies only activate T cells in combination with T-cell receptor stimulation, providing a potentially safer therapeutic approach than broader immunostimulatory agents .

How does CD27 antibody mechanism of action differ from other immunotherapeutic antibodies?

CD27 antibodies function through a distinct mechanism compared to checkpoint inhibitors like anti-PD-1 or anti-CTLA-4:

• Co-stimulation vs. checkpoint inhibition: While checkpoint inhibitors remove inhibitory signals, CD27 antibodies provide positive co-stimulatory signals that enhance T cell activation.

• Epitope-dependent agonism: The agonistic potency of CD27 antibodies depends significantly on which region of CD27 they bind to, with membrane-distal regions generally conferring stronger agonistic activity .

• Fc-dependency: The therapeutic efficacy of CD27 antibodies relies on Fc receptor engagement, particularly FcγRIIb, which facilitates receptor clustering .

• Dual mechanism: Some CD27 antibodies can both enhance immune responses and directly target CD27-expressing tumor cells through antibody-dependent cellular cytotoxicity (ADCC) .

What are the standard methods for testing CD27 antibody functionality in vitro?

Standard methods for evaluating CD27 antibody functionality include:

• T cell proliferation assays: Measuring the ability of CD27 antibodies to enhance T cell proliferation when combined with TCR stimulation (using anti-CD3 or antigen) .

• Cytokine production assessment: Quantifying the release of cytokines (particularly IFN-γ, TNF-α, and IL-2) from T cells following CD27 antibody treatment .

• Flow cytometry analysis: Assessing changes in T cell activation markers (CD25, CD69, HLA-DR) after treatment with CD27 antibodies .

• Ligand competition assays: Determining whether the antibody blocks or permits binding of the natural CD27 ligand (CD70) .

• Epitope mapping: Using truncation mutants and in silico docking analysis to identify the binding regions of CD27 antibodies, which correlates with their agonistic potential .

For optimal results, these assays should be performed with proper controls, including isotype-matched control antibodies and both positive and negative stimulation conditions.

How does epitope specificity influence the agonistic potential of CD27 antibodies?

Research has demonstrated that the specific epitope targeted by CD27 antibodies significantly impacts their agonistic potential. According to epitope mapping and in silico docking analysis:

• Antibodies binding to membrane-distal and externally-facing residues (particularly in CRD1, the first cysteine-rich domain) demonstrate stronger agonistic activity .

• Antibodies targeting membrane-proximal, internally-facing epitopes (such as those in CRD3) exhibit weaker agonistic potential .

This epitope-dependent functionality appears to be related to the antibody's ability to effectively cluster CD27 receptors. The following table summarizes the relationship between epitope region and agonistic strength:

Importantly, researchers have found that even antibodies with suboptimal epitope-dependent agonism can be partially enhanced through Fc-engineering strategies that promote receptor clustering .

What role does antibody isotype play in CD27 antibody efficacy, and how can researchers optimize isotype selection?

Antibody isotype is a critical determinant of CD27 antibody efficacy. Studies have revealed:

• Human IgG1 (h1) with enhanced affinity to Fc gamma receptor (FcγR) IIb demonstrates improved agonistic potential .

• Human IgG2 (h2) isotype naturally promotes receptor clustering, making it particularly effective for CD27 targeting .

• Mouse IgG1 (m1) binds to FcγRIIb and FcγRIII without appreciable affinity for other FcγRs, whereas mouse IgG2a (m2a) engages more strongly with activatory FcγRs and preferentially binds to FcγRI and FcγRIV .

For optimal agonistic activity, researchers should consider:

• Using human IgG1 with specific mutations that enhance binding to FcγRIIb

• Employing human IgG2 format for naturally enhanced clustering capacity

• Designing Fc-engineered antibodies that selectively engage inhibitory rather than activatory FcγRs

• Testing multiple isotype variants of promising antibody candidates to identify optimal configurations

The choice of isotype should be guided by the specific research question, as different isotypes will have varying effects on receptor clustering, immune cell engagement, and in vivo half-life.

What are the optimal experimental designs for evaluating CD27 antibody efficacy in preclinical tumor models?

Designing rigorous preclinical studies for CD27 antibodies requires consideration of several key factors:

• Model selection:

  • Syngeneic tumor models in immunocompetent mice for evaluating immune-mediated effects

  • Human CD27-transgenic mice for testing human-specific CD27 antibodies

  • SCID mice with human CD27-expressing lymphoma cells for assessing direct antitumor effects

• Dose optimization:

  • Higher doses (>1 mg/kg) are typically needed to maintain receptor occupancy

  • Dose-response studies should be conducted to determine optimal therapeutic windows

• Treatment schedule:

  • Timing relative to tumor establishment is critical (preventative vs. therapeutic)

  • Investigation of both single-agent and combination approaches

• Combination strategies:

  • CD27 antibodies show synergy with checkpoint inhibitors (anti-PD-1)

  • Combination with depleting antibodies (anti-CTLA-4, anti-CD25) has demonstrated enhanced efficacy in murine colon adenocarcinoma models

• Mechanistic studies:

  • Flow cytometric analysis of tumor-infiltrating lymphocytes

  • Assessment of memory T cell generation through rechallenge experiments

  • Depletion studies (anti-CD4, anti-CD8) to identify critical effector populations

For optimal results, researchers should consider using transgenic mice expressing human CD27 under control of its native promoter to ensure physiologically relevant expression patterns and regulation .

How can researchers address the discrepancy between preclinical efficacy and clinical outcomes of CD27 antibodies?

The translation gap between impressive preclinical results and modest clinical responses with CD27 antibodies requires systematic investigation of several factors:

• Epitope optimization:

  • Recent research suggests current clinical candidates may deliver suboptimal CD27 agonism due to non-ideal epitope targeting

  • Researchers should conduct comprehensive epitope mapping of clinical candidates and correlate with clinical outcomes

• Fc-engineering approaches:

  • Modifying antibody Fc regions to enhance FcγRIIb engagement may overcome poor epitope-dependent agonism

  • Testing systematically engineered variants with modified FcγR binding profiles

• Patient selection strategies:

  • Identifying biomarkers that predict response (CD27 expression levels, immune infiltration status)

  • Stratifying patients based on tumor CD70 expression, which may influence response to CD27 agonists

• Dosing and scheduling optimization:

  • Exploring alternative dosing schedules that maintain receptor occupancy

  • Investigating potential immunological windows for optimal intervention

• Combination approaches:

  • Systematic testing of CD27 antibodies with other immunotherapies

  • Identifying synergistic combinations through high-dimensional immune monitoring

Researchers should also consider species differences in CD27 biology and FcγR distribution that might limit the predictive value of murine models for human applications.

What are the recommended protocols for generating and characterizing novel CD27 antibodies?

The generation of novel CD27 antibodies involves several critical steps:

• Antibody generation platforms:

  • Human Ig transgenic mice immunization (as used for the 1F5 mAb/CDX-1127)

  • Phage display libraries

  • Single B-cell sorting from immunized animals

  • Rapid recombinant approach using single antigen-specific antibody-secreting cells

• Expression and purification:

  • Transient transfection of paired heavy and light chain constructs in Expi-HEK293F cells

  • Protein A or G affinity chromatography for purification

  • Endotoxin removal and sterile filtration

• Binding characterization:

  • Surface plasmon resonance for affinity determination

  • Flow cytometry to confirm binding to CD27-expressing cells

  • Epitope binning using competitive binding assays

  • Cross-reactivity testing across species (critical for translational studies)

• Functional characterization:

  • T cell activation assays with TCR co-stimulation

  • CD70 ligand competition studies

  • FcγR binding profiles

  • Epitope mapping using truncation mutants and in silico docking analysis

For generating recombinant antibodies, researchers can employ a rapid workflow involving:

• Isolation of variable region genes from single cells using nested RT-PCR

• Assembly of minigenes containing the hCMV promoter and constant regions

• Transient transfection into Expi-HEK293F cells using ExpiFectamine™ 293 Transfection Kit

What are the key considerations for designing CD27 antibody combination therapies in cancer models?

Designing effective combination strategies with CD27 antibodies requires careful consideration of several factors:

• Mechanistic rationale:

  • Combining agents with complementary mechanisms (e.g., CD27 agonist + checkpoint inhibitor)

  • Addressing multiple aspects of the cancer-immunity cycle

  • Targeting both adaptive and innate immune components

• Timing and sequencing:

  • Evaluating concurrent vs. sequential administration

  • Priming with CD27 antibody before checkpoint blockade may enhance T cell activation

  • Testing multiple schedule variations to identify optimal synergy

• Dose optimization:

  • Performing dose-response matrices to identify synergistic vs. antagonistic combinations

  • Considering potential dose reduction of individual agents in combination

• Model selection:

  • Using immunologically "cold" tumor models to assess conversion to "hot" tumors

  • Testing in models with varying baseline CD27 expression

  • Employing humanized models for translation-focused studies

• Monitoring parameters:

  • Assessing changes in tumor-infiltrating lymphocyte profiles

  • Measuring alterations in regulatory T cell populations

  • Evaluating memory T cell generation for long-term protection

Research has demonstrated particular promise for combinations of CD27 antibodies with:

• PD-1 inhibitors (enhancing anti-tumor immunity in humanized CD27 mice)

• Depleting antibodies like anti-CTLA-4 and anti-CD25 (shown effective in murine colon adenocarcinoma models)

How should researchers interpret conflicting data regarding CD27 antibody mechanisms of action?

When faced with conflicting data about CD27 antibody mechanisms, researchers should systematically evaluate:

• Experimental context differences:

  • In vitro vs. in vivo settings may yield different results

  • Variations in CD27 expression levels between model systems

  • Differences in antibody concentration and exposure time

• Epitope and isotype variations:

  • Different epitope targeting can dramatically alter functionality

  • Isotype differences significantly impact FcγR engagement and receptor clustering

  • Compare epitope mapping data when available

• Model-specific factors:

  • Expression of CD70 (CD27 ligand) in the model system

  • Background strain differences in mouse models

  • Variations in FcγR distribution between species and strains

• Technical considerations:

  • Antibody format (full IgG vs. F(ab')2 vs. Fab)

  • Purity and potential endotoxin contamination

  • Differences in readout systems and timepoints

When reporting seemingly conflicting results, researchers should clearly document:

• Detailed epitope information when available

• Complete antibody characteristics (isotype, species, modifications)

• Comprehensive experimental conditions

• Model system limitations

The literature suggests that many apparent contradictions can be resolved by understanding the relationship between epitope specificity, isotype characteristics, and the resulting agonistic potential.

What biomarkers can predict response to CD27 antibody therapy, and how should they be measured?

Several potential biomarkers may predict response to CD27 antibody therapy:

• Target expression biomarkers:

  • CD27 expression levels on peripheral and tumor-infiltrating T cells

  • CD70 (ligand) expression within the tumor microenvironment

  • Measured via flow cytometry, immunohistochemistry, or RNA sequencing

• Immune status indicators:

  • Pre-existing T cell infiltration in tumors ("hot" vs. "cold" tumors)

  • Ratio of effector to regulatory T cells

  • Expression of other co-stimulatory and co-inhibitory receptors

• Functional biomarkers:

  • T cell receptor diversity and clonality

  • HLA-DR upregulation on T cells following treatment (shown in phase I trials)

  • Reduction in regulatory T cells after therapy

• Genetic predictors:

  • Tumor mutational burden

  • Specific oncogenic pathway alterations that may influence immune recognition

  • FcγR polymorphisms that affect antibody engagement

Based on early clinical data, monitoring HLA-DR upregulation on T cells and changes in regulatory T cell populations may provide early indications of biological activity. These markers should be evaluated in peripheral blood and, when possible, in sequential tumor biopsies to assess changes in the tumor microenvironment.

What safety considerations are most important when designing first-in-human CD27 antibody trials?

Key safety considerations for first-in-human CD27 antibody trials include:

• Dose selection and escalation strategy:

  • Starting with doses well below predicted therapeutic levels

  • Implementing appropriate dose escalation rules based on preclinical toxicology

  • Considering both receptor occupancy and biological activity markers

• Monitoring parameters:

  • Cytokine release syndrome (CRS) indicators

  • Lymphocyte counts and subpopulations

  • Liver function tests and renal parameters

  • Neurological assessments

• Patient selection criteria:

  • Initial exclusion of patients with autoimmune conditions

  • Careful consideration of prior immunotherapy exposure

  • Evaluation of baseline inflammatory markers

• Risk mitigation strategies:

  • Providing clear guidelines for managing immune-related adverse events

  • Implementing stopping rules based on specific toxicity thresholds

  • Having cytokine antagonists (e.g., tocilizumab) available for severe CRS

Safety data from non-human primate studies are encouraging, with administration of up to 10 mg/kg of the CD27 antibody 1F5 being well tolerated without evidence of significant toxicity or depletion of circulating lymphocytes . Early phase I trials have further demonstrated an acceptable safety profile, with stable disease observed in patients with hematologic malignancies.

How can researchers optimize CD27 antibody development through rational engineering approaches?

Rational engineering of CD27 antibodies can enhance their therapeutic potential through several approaches:

• Epitope-guided optimization:

  • Targeting membrane-distal, externally-facing residues (particularly in CRD1) for stronger agonism

  • Using structure-guided design with crystal structures or homology models

  • Employing directed evolution or affinity maturation focusing on optimal epitopes

• Fc engineering strategies:

  • Enhancing FcγRIIb binding for improved receptor clustering

  • Using human IgG2 (h2) backbone for naturally enhanced clustering properties

  • Implementing specific mutations that selectively engage inhibitory rather than activatory FcγRs

• Bispecific formats:

  • Creating CD27 x PD-1 bispecific antibodies to simultaneously provide co-stimulation and remove inhibition

  • Developing CD27 x CD70 bispecifics to bring ligand and receptor in proximity

  • Engineering CD27 x tumor antigen bispecifics for tumor-targeted immune activation

• Novel antibody formats:

  • Trimeric or multimeric antibody constructs to enhance receptor clustering

  • Conditionally active antibodies that function primarily in the tumor microenvironment

  • pH-dependent binding antibodies with enhanced tumor specificity

The most promising engineering approaches combine optimal epitope targeting with isotype optimization. For example, antibodies binding to CRD1 with enhanced FcγRIIb binding or human IgG2 isotype have demonstrated superior agonistic potential in preclinical models .

How can CD27 antibodies be used as research tools beyond therapeutic applications?

CD27 antibodies have valuable applications as research tools:

• Immune cell phenotyping:

  • Identifying memory B cell populations (CD27+)

  • Distinguishing naive from memory T cells

  • Monitoring NK cell subsets

• Mechanistic studies of co-stimulation:

  • Investigating CD27-dependent signaling pathways

  • Studying differential effects of CD27 engagement on diverse immune subsets

  • Exploring the interplay between CD27 and other co-stimulatory receptors

• T cell manipulation ex vivo:

  • Enhancing expansion of antigen-specific T cells for adoptive transfer

  • Modulating memory T cell generation

  • Inducing specific cytokine profiles

• Developmental immunology:

  • Tracking thymocyte development (CD27 expression changes during T cell maturation)

  • Studying the role of CD27 in B cell differentiation

  • Investigating CD27's contribution to germinal center reactions

• Flow cytometry applications:

  • The LG.7F9 monoclonal antibody can be used at ≤0.125 μg per test for flow cytometric analysis

  • It has cross-reactivity with human and rat CD27, making it valuable for comparative studies

For optimal use as research reagents, researchers should carefully select antibody clones based on their specific binding properties, cross-reactivity, and functional characteristics.

What are the best practices for validating CD27 antibody specificity and functionality in different experimental systems?

Comprehensive validation of CD27 antibodies should include:

• Specificity testing:

  • Flow cytometry on CD27-positive and CD27-negative cell lines

  • Testing on cells from CD27 knockout animals

  • Western blot analysis with recombinant CD27 protein

  • Cross-reactivity assessment across relevant species

• Epitope characterization:

  • Competition with other validated anti-CD27 clones

  • Testing binding to CD27 truncation mutants

  • Evaluating competition with CD70 (natural ligand)

  • In silico docking analysis to predict binding regions

• Functional validation:

  • Assessing T cell activation in combination with TCR stimulation

  • Measuring cytokine production (IFN-γ, TNF-α, IL-2)

  • Evaluating proliferative responses of target cells

  • Testing agonistic activity with appropriate controls

• Isotype controls:

  • Including matched isotype controls in all experiments

  • Ensuring isotype controls undergo the same manufacturing processes

  • Confirming lack of non-specific effects from isotype controls

• Batch-to-batch consistency:

  • Implementing quality control processes

  • Maintaining reference standards

  • Documenting lot-specific activity metrics

For flow cytometry applications, the LG.7F9 antibody has been tested for optimal performance in the range of 10^5 to 10^8 cells/test, but researchers should empirically determine the optimal cell concentration for their specific application .

How do CD27 antibodies compare with other TNFR superfamily-targeting antibodies in research and therapeutic applications?

CD27 antibodies have distinct properties compared to other TNFR superfamily-targeting antibodies:

• Target expression profile:

  • CD27: Predominantly on lymphocytes (T cells, B cells, NK cells)

  • CD40: B cells, dendritic cells, macrophages

  • OX40 (CD134): Primarily activated T cells

  • 4-1BB (CD137): Activated T cells, NK cells

• Mechanism distinctions:

  • CD27 antibodies: T cell co-stimulation dependent on TCR engagement

  • CD40 antibodies: Primarily activate antigen-presenting cells

  • OX40 antibodies: Enhance effector T cell expansion and survival

  • 4-1BB antibodies: Promote CD8+ T cell responses and memory formation

• Safety profile differences:

  • CD27 antibodies: Generally well-tolerated without significant lymphocyte depletion

  • CD40 antibodies: Often associated with cytokine release and liver toxicity

  • OX40 antibodies: Typically mild adverse effects

  • 4-1BB antibodies: History of liver toxicity in clinical studies

• Combinatorial approaches:

  • CD27 + checkpoint inhibitors: Enhanced efficacy in preclinical models

  • CD40 + chemotherapy: Synergy through immunogenic cell death

  • OX40 + vaccination: Improved antigen-specific responses

  • 4-1BB + radiotherapy: Increased abscopal effects

• Clinical development status:

  • CD27: Several candidates in early clinical development (e.g., CDX-1127/varlilumab)

  • CD40: Multiple agents in phase I/II trials

  • OX40: Several candidates with modest single-agent activity

  • 4-1BB: Development challenged by toxicity concerns

CD27 antibodies offer a potentially favorable therapeutic window due to their dependency on TCR engagement for activation, potentially limiting off-target effects compared to some other TNFR-targeting approaches .